

IN THE CLAIMS

1. (currently amended) A dry powder inhalation composition consisting of (a) at least ~~0.25%~~ 0.26% by weight of the composition of an active ingredient comprising albuterol with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size of less than 250 microns in diameter.

2. (previously presented) The dry powder inhalation composition according to claim 1, wherein the composition comprises less than 10% by weight of the composition of the active ingredient.

3. (currently amended) The dry powder inhalation composition according to claim 1 or claim 2, wherein the composition comprises from ~~about~~ at least 0.26 to about 1% by weight of the composition of the active ingredient.

4. (previously presented) The dry powder inhalation composition according to claim 1, which comprises from about 0.265 to about 0.5% by weight of the composition of the active ingredient.

5. (previously presented) The dry powder inhalation composition according to claim 1 or 4, wherein the carrier is lactose.

6. (canceled).

7. (Canceled).

8. (previously presented) A capsule containing from 1 to 25 mg of a dry powder inhalation composition according to claim 1 or 4.

9. (previously presented) A multidose dry powder inhaler comprising a reservoir containing the dry powder inhalation composition of claim 1 or 4.

10. (previously presented) A method for the treatment of chronic obstructive pulmonary disease by the step of administering the dry powder inhalation composition of claim 1 or 4.

11. (currently amended) A dry powder inhalation composition consisting of (a) at least ~~0.25%~~ 0.26% by weight of the composition of an active ingredient comprising albuterol with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 89 to about 110 microns in diameter.

12. (currently amended) A dry powder inhalation composition consisting of (a) at least ~~0.25%~~ 0.26% by weight of the composition of an active ingredient comprising albuterol with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 50 to about 60 microns in diameter.

13. (currently amended) A dry powder inhalation composition consisting of (a) at least ~~0.25%~~ 0.26% by weight of the composition of an active ingredient comprising albuterol with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 60 to about 90 microns in diameter.

14. (currently amended) The dry powder inhalation composition according to claim 9, wherein ~~said active ingredient is formoterol and~~ said multidose dry powder inhaler is capable of producing a 6 mcg dose having a fine particle fraction of 48%.

15. (currently amended) The dry powder inhalation composition according to claim 9, wherein ~~said active ingredient comprises formoterol and~~ said multidose dry powder inhaler is capable of producing a 12 mcg dose having a fine particle fraction of 49%-54%.

16. (canceled).